Pill-based pre-CAR-T therapy for high-risk B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new way to prepare for CAR-T cell therapy for people with aggressive B-cell lymphoma who cannot have a stem cell transplant. Instead of using strong chemotherapy before CAR-T, this trial uses a pill-based regimen to keep the cancer under control and help the CAR-T cells work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of B-cell lymphoma (like diffuse large B-cell lymphoma, transformed follicular lymphoma, or some others).
- Your lymphoma came back or didn't respond to at least one previous treatment, and your doctor has decided that high-dose chemotherapy with a stem cell transplant is not right for you.
- Your largest tumor is bigger than 4 centimeters, and you have a measurable spot on imaging (like a lymph node at least 1.5 cm).
- Your blood counts, kidney, liver, and lung function meet certain minimum levels, and your heart pumps well enough.
- You have not had CAR-T therapy before, no active hepatitis B or C, no HIV, and no other uncontrolled infections or recent cancers.
- You are willing to avoid pregnancy, have not had a live vaccine in the last 3 months, and can give your consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.